India’s Drug Regulator Flags 27 Batches of Essential Medicines, Including Paracetamol and Ibuprofen, as ‘Not of Standard Quality’

NEW DELHI — In a major public health alert highlighting ongoing quality surveillance across India’s pharmaceutical supply chain, the nation’s central drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has declared 27 batches of medicines and one medical device as “Not of Standard Quality” (NSQ).

The public notification, released in late July 2026, covers testing conducted during June 2026 across central testing laboratories. The flagged list spans widely used over-the-counter pain relievers, pediatric formulations, anti-epileptic medications, and emergency injectable therapies. Regulators issued the alert to trigger immediate recall mechanisms, assist health authorities, and prevent defective pharmaceutical batches from reaching patients in retail pharmacies and hospital settings.

Key Findings: Scope of Quality Failures

The monthly NSQ report published by the CDSCO revealed failure points across multiple therapeutic categories and dosage forms, including oral liquids, solid tablets, topical ointments, sterile injectables, and single-use medical devices.

Among the flagged formulations were everyday healthcare staples:

• Pediatric Pain and Fever Care: Specific batches of Paracetamol Paediatric Oral Suspension IP failed regulatory checks due to assay and pH deviations.

• Anti-Inflammatory & Analgesic Drugs: Ibuprofen tablets and Etodolac tablets IP showed sub-standard performance in dissolution and active ingredient content testing.

• Neurological & Anti-Epileptic Therapies: Batches of Levetiracetam tablets IP (1000 mg) and Phenytoin Sodium injections failed specified standards for physical description, hardness, or ingredient uniformity.

• Cardiovascular & Gastrointestinal Medications: Adenosine injections, Montelukast tablets, and Pantoprazole gastro-resistant tablets exhibited serious non-compliance in analytical testing.

• Medical Supplies: A single batch of single-use disposable syringes failed essential sterility testing, presenting an immediate bioburden risk.

Laboratory analysis identified a wide spectrum of defects. Non-conformities ranged from dissolution failures—where a tablet fails to dissolve and release its active drug at the intended rate—to assay failures, which indicate that the product contained too much or too little active pharmaceutical ingredient (API).

Crucially, one specific batch of Adenosine Injection IP (6 mg/2 mL) manufactured by Welcure Remedies was classified under Section 17B of India’s Drugs and Cosmetics Act as spurious after failing comprehensive checks for identification, sterility, particulate matter, bacterial endotoxins, and active content.

Expert Commentary: Understanding Batch-Level Risks

While the inclusion of household names like paracetamol and ibuprofen may trigger initial alarm among consumers, medical experts emphasize the importance of interpreting the report in its proper regulatory context.

“It is critical for both the medical community and the public to realize that an NSQ notification is a surgical, batch-specific warning — not a blanket ban on a drug or a brand,” explains Dr. Anjali Mehta, a clinical pharmacologist and professor of medicine at a tertiary-care teaching hospital in New Delhi. “When CDSCO flags a batch, it means that particular manufacturing lot failed quality parameters during random surveillance sampling. The core purpose of publishing these alerts monthly is risk mitigation: catching defects before they lead to widespread clinical treatment failure or adverse reactions.”

Dr. Mehta notes that quality deviations carry varying levels of clinical severity depending on the route of administration and the target patient population:

• Oral Formulations: A tablet that fails dissolution testing may simply pass through the digestive tract without delivering therapeutic benefit, leading to unmanaged fever, pain, or breakthrough seizures in patients taking anti-epileptic drugs like levetiracetam.

• Sterile Injectables & Medical Devices: Sterility failures, high particulate counts, or endotoxin contamination in intravenous injections or syringes pose far higher immediate dangers, including bloodstream infections, phlebitis, or systemic inflammatory responses.

• Pediatric Care: Children and infants are particularly vulnerable to dosing inaccuracies caused by pH or assay deviations in liquid suspensions.

Regulatory Context and Systemic Surveillance

India’s pharmaceutical industry supplies a vast portion of global and domestic medicines. To maintain safety standards, state and central regulatory bodies conduct routine, unannounced sampling at distribution points, manufacturing plants, and retail pharmacies.

Monthly alerts published on the CDSCO online portal serve as an early-warning registry for state drug controllers, hospital procurement committees, and retail pharmacists. Similar regulatory actions have been documented in preceding months and years; for instance, a major CDSCO drive in September 2024 flagged more than 50 widely distributed drug batches for similar quality lapses.

Legal classifications within these reports carry distinct regulatory meanings:

1. Not of Standard Quality (NSQ): Products that fail standard pharmacopeial tests (e.g., dissolution, uniform weight, or shelf-life stability) due to manufacturing errors, poor raw material quality, or improper storage conditions.

2. Spurious / Counterfeit: Products manufactured deceptively, often mimicking established brands, containing substitute substances, or lacking genuine active ingredients entirely.

The June 2026 CDSCO report identified 26 batches as NSQ and labeled 1 batch of injectable medication as spurious, illustrating that the vast majority of flagged issues stem from quality control lapses during synthesis, packaging, or storage rather than intentional counterfeiting.

Public Health Implications and Guidance for Consumers

For healthcare providers and hospital administrators, the release of the NSQ list requires immediate cross-referencing with pharmacy inventories to ensure that affected batch numbers are quarantined and returned to distributors.

For general consumers, health authorities advise measured vigilance rather than panic:

• Check Batch Numbers: Look at the side or back of blister packs and bottle labels. Compare the printed batch number against official CDSCO alerts if you suspect a quality issue.

• Inspect Physical Appearance: Do not ingest or administer medicines that show signs of discoloration, crumbling tablets, unusual odor, sediment in oral liquids, or broken seals.

• Do Not Stop Essential Medications: Patients taking maintenance medications for chronic conditions—such as epilepsy therapies (levetiracetam or phenytoin)—must never stop their treatment abruptly. If you suspect your prescription belongs to a flagged batch, consult your pharmacist or physician immediately for a safe, equivalent replacement.

• Purchase from Licensed Pharmacies: Ensure all healthcare products are bought from reputably licensed retail or hospital pharmacies that maintain verifiable supply-chain records.

Limitations of Surveillance Data

Public health experts caution that published NSQ lists provide a snapshot of regulatory testing rather than a complete statistical survey of overall drug quality across the market. Because testing relies on targeted and random sampling strategies, a low number of flagged batches in a specific category does not guarantee absolute safety across uninspected lots, nor does a spike in flags mean the broader pharmaceutical supply is unsafe.

Furthermore, environmental degradation during transport and storage—such as exposure to high heat or humidity in warehouses—can cause genuine batches to fail stability testing post-distribution. Regulatory agencies continue to expand cold-chain monitoring and enforce updated Good Manufacturing Practices (GMP) to address these systemic vulnerabilities.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Medical Dialogues. “CDSCO Flags 27 Drug Batches Including Paracetamol, Ibuprofen, Levetiracetam as Not of Standard Quality.” Published July 22, 2026. Available at: https://medicaldialogues.in